Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR ‐ TKIs ( ML41256 ): A Multicenter, Prospective, Single‐Arm, Phase 2 Trial

Documenti analoghi

• Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial
  di: Huiyang Shi, et al.
  Pubblicazione: (2025)
• Clinical Outcomes of Later‐Generation EGFR ‐ TKIs for Uncommon EGFR Mutations in NSCLC : A Multicenter Real‐World Study
  di: Lisa Shigematsu, et al.
  Pubblicazione: (2025)
• Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
  di: Jin Tian, et al.
  Pubblicazione: (2024)
• Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B
  di: Ryu Sasaki, et al.
  Pubblicazione: (2025)
• Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC
  di: Xin Xiang, et al.
  Pubblicazione: (2026)